Pharmaron (03759) announced that in order to give full play to the advantages of its leading medical and health field and global industry chain, and to help innovative medical enterprises grow, promote an open, cooperative and win-win medical innovation ecosystem expansion, and jointly promote the development of the medical and health industry, the company has reached a comprehensive strategic cooperation with AstraZeneca Investment (China) Co., Ltd. (hereinafter referred to as "AstraZeneca China") including small molecules, large molecules, cell and gene therapy drugs, covering the entire process of drug discovery, pre-clinical and clinical development, commercial production integration services, and investment in innovative drug R&D. In addition, based on the active role of AstraZeneca China's innovation "three carriages", AstraZeneca Fund in promoting China's innovative drug industry, the company intends to make additional capital contributions to AstraZeneca Fund by acquiring the fund shares held by Jiangsu Yuyue Medical Equipment Co., Ltd. and Shanghai Zhengxingu Investment Management Co., Ltd. that have been subscribed but not yet paid in, at a total amount of RMB 91 million yuan.
On August 16, 2024, the company, CICC Private Equity Investment Management Co., Ltd. and AstraZeneca Business Consulting (Wuxi) Co., Ltd. signed the Property Share Transfer Agreement regarding the CICC-AstraZeneca Innovation Investment Enterprise (Limited Partnership). The company acquired the AstraZeneca Fund shares held by Yuyue Medical and Zhengxingu at a cost of RMB 80 million yuan and RMB 11 million yuan respectively, which have been subscribed but not yet paid for, with a consideration of RMB 0 yuan. Other limited partners of AstraZeneca Fund do not have the preemptive right to purchase the fund shares acquired by the company in this transaction. After the additional investment is completed, the company's subscribed AstraZeneca Fund shares total RMB 191 million yuan, accounting for 8.46% of the total subscribed shares of AstraZeneca Fund.
Please use your Futubull account to access the feature.